	380	mm	
187.5	mm	35 mm	157.5 mm
		5 2 3 0 0 8 9 Lacosamide Tablets	
HIGHLIGHTS OF PRESCRIBING INFORMATION	CONTRAINDICATIONS None (4)	with lacosamide reported an adverse reaction of syncope or loss of consciousness, compared with 0% of placebo-treated patients with diabetic neuropathy. Most of the cases of syncope were observed in patients	In two studies in which lacosamide (25, 70, or 200 mg/kg/day and 50, 100, or 200 mg/k administered to rats throughout pregnancy and lactation, increased perinatal mortality and
These highlights do not include all the information needed to use LACOSAMIDE TABLETS safely and effectively. See full prescribing information for LACOSAMIDE TABLETS.	WARNINGS AND PRECAUTIONS Monitor patients for suicidal behavior and ideation (5.1)	receiving doses above 400 mg/day. The cause of syncope was not determined in most cases. However, several were associated with either changes in orthostatic blood pressure, atrial flutter/fibrillation (and associated tachycardia), or bradycardia. Cases of syncope have also been observed in open-label clinical partial-onset seizure studies in adult and pediatric patients. These cases were associated with a history of risk factors for cardiac disease and the use of drugs that slow AV conduction.	weights in the offspring were observed at the highest dose tested. The no-effect dose for developmental toxicity in rats (70 mg/kg/day) was associated with a maternal plasma lacosan that in humans at the MRHD. Oral administration of lacosamide (30, 90, or 180 mg/kg/day) to rats during the neonatal and
LACOSAMIDE tablets, for oral use, 文 Initial U.S. Approval: 2008	 Lacosamide may cause dizziness and ataxia (5.2) Cardiac Rhythm and Conduction Abnormalities: Obtaining ECG before beginning and after titration to steady-state maintenance is recommended in patients with underlying proarrhythmic conditions or on concomitant medications that affect 	5.5 Withdrawal of Antiepileptic Drugs (AEDs) As with all AEDs, lacosamide should be withdrawn gradually (over a minimum of 1 week) to minimize the potential of increased seizure frequency in patients with seizure disorders.	development resulted in decreased brain weights and long-term neurobehavioral changes performance, deficits in learning and memory). The early postnatal period in rats is get correspond to late pregnancy in humans in terms of brain development. The no-effect dose neurotoxicity in rats was associated with a plasma lacosamide AUC less than that in humans at
RECENT MAJOR CHANGES Indications and Usage (1.1) 10/2021	 cardiac conduction; closely monitor these patients (5.3, 7.2) Lacosamide may cause syncope (5.4) Lacosamide should be gradually withdrawn to minimize the potential of increased 	5.6 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multi-Organ Hypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity, has been reported in patients taking antiepileptic drugs, including lacosamide. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy	In Vitro Data Lacosamide has been shown in vitro to interfere with the activity of collapsin response r (CRMP-2), a protein involved in neuronal differentiation and control of axonal outgrowth. Poten on CNS development related to this activity cannot be ruled out.
Dosage and Administration (2.1) 10/2021	 Seizure frequency (5.5) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/ Multi-Organ Hypersensitivity: Discontinue if no alternate etiology (5.6) 	and/or facial swelling, in association with other organ system involvement out, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophila is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may	8.2 Lactation <u>Risk Summary There are no data on the presence of lacosamide in human milk, the effects on the breastfed in </u>
 Lacosamide is indicated for: Treatment of partial-onset seizures in patients 4 years of age and older (1.1) 	Adverse Reactions Adverse reactions in adults (≥10% and greater	be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Lacosamide should be discontinued if an alternative etiology for the signs or symptoms cannot be established.	on milk production. Studies in lactating rats have shown excretion of lacosamide and/or its metr The developmental and health benefits of breastfeeding should be considered along with th need for lacosamide and any potential adverse effects on the breastfed infant from lacosa
DOSAGE AND ADMINISTRATION Adults (17 years and older): Initial dosage for monotherapy for the treatment of partial-onset seizures is 100 mg twice daily (2.1) Initial dosage for adjunctive therapy for the treatment of partial-onset seizures is 50 mg twice daily (2.1) Maximum recommended dosage for monotherapy and adjunctive therapy is	 Adjunctive therapy. Most common adverse reactions in addits (≥ 10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence (6.1) Monotherapy: Most common adverse reactions are similar to those seen in adjunctive therapy studies (6.1) Pediatric patients: Adverse reactions are similar to those seen in adult patients (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical 	 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Suicidal Behavior and Ideation [see Warnings and Precautions (5.1)] Dizziness and Ataxia [see Warnings and Precautions (5.2)] Cardiac Rhythm and Conduction Abnormalities [see Warnings and Precautions (5.3)] Syncope [see Warnings and Precautions (5.4)] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions [see Warnings and Precautions (5.6)] 	underlying maternal condition. 8.4 Pediatric Use <u>Partial-Onset Seizures</u> Safety and effectiveness of lacosamide for the treatment of partial-onset seizures have be pediatric patients 4 years to less than 17 years of age. Use of lacosamide in this age group evidence from adequate and well-controlled studies of lacosamide in adults with partia pharmacokinetic data from adult and pediatric patients, and safety data in 328 pediatric patient than 17 years of age [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and
 200 mg twice daily (2.1) Pediatric Patients 4 years to less than 17 years: The recommended dosage is based on body weight and is administered orally twice daily (2.1) 	Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch	6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.	(14.1, 14.2)]. Safety and effectiveness in pediatric patients below 1 month of age have not been established.
 Increase dosage based on clinical response and tolerability, no more frequently than once per week (2.1) Dose adjustment is recommended for severe renal impairment (2.3, 12.3) Dose adjustment is recommended for mild or moderate hepatic impairment; use in patients with severe hepatic impairment is not recommended (2.4, 12.3) 	Oregnancy: Based on animal data, may cause fetal harm (8.1) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide	<u>Lacosamide Tablet in Adults</u> In the premarketing development of adjunctive therapy for partial-onset seizures, 1,327 adult patients received lacosamide tablets in controlled and uncontrolled trials, of whom 1,000 were treated for longer than 6 months, and 852 for longer than 12 months. The monotherapy development program for partial-onset seizures included 425 adult patients, 310 of whom were treated for longer than 6 months, and 254 for longer than 12 months.	<u>Animal Data</u> Lacosamide has been shown <i>in vitro</i> to interfere with the activity of collapsin response -2 (CRMP-2), a protein involved in neuronal differentiation and control of axonal outgrowth adverse effects on CNS development cannot be ruled out. Administration of lacosamide t neonatal and juvenile periods of postnatal development (approximately equivalent to neonatal It development in humans) resulted in decreased brain weights and long-term neurobehavioral open field performance, deficits in learning and memory). The no-effect dose for development
 50 mg, 100 mg, 150 mg, 200 mg tablets (3) 	Additional pediatric use information is approved for UCB, Inc.'s VIMPAT [®] (lacosamide) tablets. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.	Partial-Onset Seizures Monotherapy Historical-Control Trial (Study 1) In the monotherapy trial for partial-onset seizures, 16% of patients randomized to receive lacosamide at the recommended doses of 300 and 400 mg/day discontinued from the trial as a result of an adverse reaction. The adverse reaction most commonly (≥ 1% on lacosamide) leading to discontinuation was dizziness.	rats was associated with a plasma lacosamide exposure (AUC) less than that in humans recommended human dose of 400 mg/day. Additional pediatric use information is approved for UCB, Inc.'s VIMPAT [®] (lacosamide) tablets UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric infor
	Revised: 03/2022	Adverse reactions that occurred in this study were generally similar to those that occurred in adjunctive placebo- controlled studies. One adverse reaction, insomnia, occurred at a rate of $\geq 2\%$ and was not reported at a similar rate in previous studies. This adverse reaction has also been observed in postmarketing experience [see Adverse	8.5 Geriatric Use There were insufficient numbers of elderly patients enrolled in partial-onset seizure trials (n= determine whether they respond differently from younger patients.
FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Partial-Onset Seizures 2 DOSAGE AND ADMINISTRATION	8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use	Reactions (6.2)]. Because this study did not include a placebo control group, causality could not be established. Dizziness, headache, nausea, somnolence, and fatigue all occurred at lower incidences during the AED Withdrawal Phase and Monotherapy Phase, compared with the Titration Phase <i>[see Clinical Studies (14.1)]</i> .	No lacosamide dose adjustment based on age is necessary. In elderly patients, dose is performed with caution, usually starting at the lower end of the dosing range, reflecting the g decreased hepatic function, decreased renal function, increased cardiac conduction a polypharmacy [see Dosage and Administration (2.1, 2.3, 2.4) and Clinical Pharmacology (12.
2 Dosage Information 2.1 Dosage Information 2.2 Converting From a Single Antiepileptic (AED) to Lacosamide Monotherapy for the Treatment of Partial-Onset Seizures 2.3 Dosage Information for Patients with Renal Impairment 2.4 Dosage Information for Patients with Renal Impairment	8.6 Renal Inpairment 8.7 Hepatic Impairment 9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance 9.2 Abuse	Adjunctive Therapy Controlled Trials (Studies 2, 3, and 4) In adjunctive therapy controlled clinical trials for partial-onset seizures, the rate of discontinuation as a result of an adverse reaction was 8% and 17% in patients randomized to receive lacosamide at the recommended doses of 200 and 400 mg/day, respectively, 29% at 600 mg/day (1.5 times greater than the maximum recommended dose), and 5% in patients randomized to receive placebo. The adverse reactions most commonly (>1% on	8.6 Renal Impairment Based on data in adults, no dose adjustment is necessary in adult and pediatric patients with renal impairment ($CL_{cn} \ge 30$ mL/min). In adult and pediatric patients with severe ($CL_{cn} < 30$ mL/min) and in those with end-stage renal disease, a reduction of 25% of the ma

Void Code: **5229822** Void A/W Reason: Revised as per FDA Model Labeling Dated March 09, 2022 Dimension: 380x570 mm Country: USA Language: ENGLISH Mfg. Location: DADRA Specification/Type of Paper: Super Fine 41 GSM ITC Paper Folding: Open size : 380x570 mm

Artwork Type: PACKAGE OUTSERT

Artwork Code: 5230089

Lacosamide Tablets

Dosage Information for Patients with Hepatic Impairment

OVERDOSAGE

andomized to receive placebo. The adverse reactions most co lacosamide and greater than placebo) leading to discontinuation were dizziness, ataxia, vomiting, diplopia, nausea, vertigo, and blurred vision.

recommended [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].

In all patients with renal impairment, dose titration should be performed with cautior

Closing size:34x35 mm

Special Req.: -

 \bigcirc

SUN PHARMA

Remark (if any):

Prepared by: SAPNA

Approved by RA:

APPROVAL HISTORY ATTACHED

No. of Colors: 1

Black

Suicidal Behavior and Ideation 12.1 12.2 Dizziness and Ataxia Pharmacodynamics 5.3 Cardiac Rhythm and Conduction Abnormalities 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY Syncope Withdrawal of Antiepileptic Drugs (AEDs) 14 CLINICAL STUDIES 5.6 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multi-Organ Hypersensitivity 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience6.2 Postmarketing Experience 16 HOW SUPPLIED/STORAGE AND HANDLING 7 DRUG INTERACTIONS 16.1 How Supplied 7.1 Strong CYP3A4 or CYP2C9 Inhibitors 7.2 Concomitant Medications that Affect Cardiac Conduction 16.2 Storage and Handling 17 PATIENT COUNSELING INFORMATION FULL PRESCRIBING INFORMATION 2.7 Discontinuation of Lacosamide Tablets When discontinuing lacosamide tablets, a gradual withdrawal over at least 1 week is recommended [see Warnings and Precautions (5.5)]. INDICATIONS AND USAGE 1.1 Partial-Onset Seizures nide tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. DOSAGE FORMS AND STRENGTHS Additional pediatric use information is approved for UCB, Inc.'s VIMPAT® (lacosamide) tablets. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. amide tablets, USP

DOSAGE AND ADMINISTRATION 2.1 Dosage Information

once per week. Titration increments should not exceed those shown in Table 1.

Administration Instructions for Lacosamide Tablets

Discontinuation of Lacosamide Tablets

DOSAGE FORMS AND STRENGTHS

WARNINGS AND PRECAUTIONS

CONTRAINDICATIONS

e recommended dosage for monotherapy and adjunctive therapy for partial-onset seizures in patients 4 years of age and older is included in Table 1. In pediatric patients, the recommended dosing regimen is dependent upon body weight. Dosage should be increased based on clinical response and tolerability, no more frequently than

Table 1: Recommended Do 4 Years of Age and Older* commended Dosages for Partial-Onset Seizures (Monotherapy or Adjunctive Therapy) in Patients

i outo of figo and ofaot			
Age and Body Weight	Initial Dosage	Titration Regimen	Maintenance Dosage
Adults (17 years and older)	Monotherapy**: 100 mg twice daily (200 mg per day) Adjunctive Therapy: 50 mg twice daily (100 mg per day)	Increase by 50 mg twice daily	Monotherapy**: 150 mg to 200 mg twice daily (300 mg to 400 mg per day)
	Alternative Initial Dosage: 200 mg single loading dose, followed 12 hours later by 100 mg twice daily	(100 mg per day) every week	Adjunctive Therapy: 100 mg to 200 mg twice daily (200 mg to 400 mg per day)
Pediatric patients weighing 50 kg or more	50 mg twice daily (100 mg per day)	Increase by 50 mg twice daily (100 mg per day) every week	Monotherapy**: 150 mg to 200 mg twice daily (300 mg to 400 mg per day) Adjunctive Therapy: 100 mg to 200 mg twice daily (200 mg to 400 mg per day)
Pediatric patients weighing 30 kg to less than 50 kg	1 mg/kg twice daily (2 mg/kg/day)	Increase by 1 mg/kg twice daily (2 mg/kg/day) every week	2 mg/kg to 4 mg/kg twice daily (4 mg/kg/day to 8 mg/kg/day)
Pediatric patients weighing 11 kg to less than 30 kg	1 mg/kg twice daily (2 mg/kg/day)	Increase by 1 mg/kg twice daily (2 mg/kg/day) every week	3 mg/kg to 6 mg/kg twice daily (6 mg/kg/day to 12 mg/kg/day)
when not specified, the dosage is the same for monotherapy for partial-onset seizures and adjunctive herapy for partial-onset seizures.			

**Monotherapy for partial-onset seizures only

In adjunctive clinical trials in adult patients with partial-onset seizures, a dosage higher than 200 mg twice daily (400 mg per day) was not more effective and was associated with a substantially higher rate of adverse reactions [see Adverse Reactions (6.1) and Clinical Studies (14.2)].

Loading Dose in Adult Patients (17 Years and Older)

Lacosamide tablets may be initiated in adult patients with a single loading dose of 200 mg, followed approximately 12 hours later by 100 mg twice daily (200 mg per day).

The maintenance dose regimen should be continued for one week. Lacosamide can then be titrated as recommended in Table 1. The adult loading dose should be administered with medical supervision because of the increased incidence of CNS adverse reactions [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)].

The use of a loading dose in pediatric patients has not been studied.

Additional pediatric use information is approved for LICR Inc.'s VIMPAT® (lacosamide) tablets. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

2.2 Converting From a Single Antiepileptic (AED) to Lacosamide Monotherapy for the Treatment of Partial-Onset Seizures

For patients who are already on a single AED and will convert to lacosamide monotherapy, withdrawal of the concomitant AED should not occur until the therapeutic dosage of lacosamide is achieved and has been administered for at least 3 days. A gradual withdrawal of the concomitant AED over at least 6 weeks is

2.3 Dosage Information for Patients with Renal Impairment For patients with mild to moderate renal impairment, no dosage adjustment is necessary.

For patients with severe renal impairment [creatinine clearance (CL_{col}) less than 30 mL/min as estimated by the Cockcroft-Gault equation for adults; CL_{col} less than 30 mL/min/1.73 m² as estimated by the Schwartz equation for pediatric patients] or end-stage renal disease, a reduction of 25% of the maximum dosage is recommended.

In all patients with renal impairment, the dose titration should be performed with caution.

Hemodialysis

Lacosamide is effectively removed from plasma by hemodialysis. Following a 4-hour hemodialysis treatment. dosage supplementation of up to 50% should be considered

2.4 Dosage Information for Patients with Hepatic Impairment

<u>Concomitant Strong CYP3A4 or CYP2C9 Inhibitors</u> Dose reduction may be necessary in patients with renal impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 [see Drug Interactions (7.1), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].

For patients with mild or moderate hepatic impairment, a reduction of 25% of the maximum dosage is

Lacosamide Tablets 12 CLINICAL PHARMACOLOGY Mechanism of Action

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

- 14.1 Monotherapy in Patients with Partial-Onset Seizures
- 14.2 Adjunctive Therapy in Patients with Partial-Onset Seizures

* Sections or subsections omitted from the full prescribing information are not listed.

- 50 mg: light pink, oval, biconvex, film-coated tablets debossed with "918" on one side and plain on other side 100 mg: yellow, oval, biconvex, film-coated tablets debossed with "922" on one side and plain on other side
 - Too mg, yanav, ovar, nichoreka, min-tocated tablets debossed with "943" on one side and plain on other side
 200 mg; blue, oval, biconvex, film-coated tablets debossed with "943" on one side and plain on other side

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS Suicidal Behavior and Ideation

Antiepilepilic drugs (AEDS), including lacosamide, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

Table 2 shows absolute and relative risk by indication for all evaluated AEDs.

Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis

Indication	Placebo Patients with Events Per 1,000 Patients	Drug Patients with Events Per 1,000 Patients	Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients	Risk Difference: Additional Drug Patients with Events Per 1,000 Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar.

Anyone considering prescribing lacosamide or any other AED must balance this risk with the risk of untreated illness. Epilepsy and many other illnesses for which antiepileptics are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

5.2 Dizziness and Ataxia

Lacosamide may cause dizziness and ataxia in adult and pediatric patients. In adult patients with partial-onset seizures taking 1 to 3 concomitant AEDs, dizziness was experienced by 25% of patients randomized to the recommended doses (200 to 400 mg/day) of lacosamide (compared with 8% of placebo patients) and was the adverse event most frequently leading to discontinuation (3%). Ataxia was experienced by 6% of patients randomized to the recommended doses (200 to 400 mg/day) of lacosamide (compared to 2% of placebo patients). The onset of dizziness and ataxia was most commonly observed during titration. There was a substantial increase in these adverse events at doses higher than 400 mg/day [see Adverse Reactions (6.1)].

5.3 Cardiac Rhythm and Conduction Abnormalities

PR Interval Prolongation. Atrioventricular Block. and Ventricular Tachyarrhythmia Dose-dependent prolongations in PR interval with lacosamide have been observed in clinical studies in adult patients and in healthy volunteers [see Clinical Pharmacology (12.2)]. In adjunctive clinical trials in adult patients patients and in heading volumeers (see climite, in harmedowy (12.2.7), in adjunctive climites in adult patients with partial-noiset seizures, asymptomatic first-degree atrioventricular (AV) block was observed as an adverse reaction in 0.4% (4/944) of patients randomized to receive lacosamide and 0% (0/364) of patients randomized to receive placebo. One case of profound bradycardia was observed in a patient during a 15-minute infusion of 150 mg lacosamide. When lacosamide is given with other drugs that prolong the PR interval, further PR prolongation is possible.

In the postmarketing setting, there have been reports of cardiac arrhythmias in patients treated with lacosamide, including bradycardia, AV block, and ventricular tachyarrhythmia, which have rarely resulted in asystole, cardiac arrest, and death. Most, although not all, cases have occurred in patients with underlying proarrhythmic conditions, or in those taking concomitant medications that affect cardiac conduction or prolong the PR interval. These events have occurred with both oral and intravenous routes of administration and at prescribed doses as well as in the setting of overdose [see Overdosage (10)].

Lacosamide should be used with caution in patients with underlying proarrhythmic conditions such as known cardiac conduction problems (e.g., marked first-degree AV block, second-degree or higher AV block and sick sinus syndrome without pacemaker), severe cardiac disease (such as myocardial ischemia or heart failure, or structural heart disease), and cardiac sodium channelopathies (e.g., Brugada Syndrome). Lacosamide should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2)]. In such patients, obtaining an ECG before beginning lacosamide, and after lacosamide is titrated to steady-state maintenance dose, is recommended. In addition, these patients should be closely monitored if they are administered lacosamide through the intravenous route [see Adverse Reactions (6.1) and Drug Interactions (7.2)].

Table 3 gives the incidence of adverse reactions that occurred in \geq 2% of adult patients with partial-onset seizures in the lacosamide total group and for which the incidence was greater than placebo.

Table 3: Adverse Reactions Incidence in Adjunctive Therapy Pooled, Placebo-Controlled Trials in Adult Patients with Partial-Onset Seizures (Studies 2, 3, and 4)

Adverse Reaction	Placebo N=364 %	Lacosamide 200 mg/day N=270 %	Lacosamide 400 mg/day N=471 %	Lacosamide 600 mg/day N=203 %	Lacosamide Total N=944 %
Ear and labyrinth disord	ler				
Vertigo	1	5	3	4	4
Eye disorders					
Diplopia	2	6	10	16	11
Blurred Vision	3	2	9	16	8
Gastrointestinal disorde	ers				
Nausea	4	7	11	17	11
Vomiting	3	6	9	16	9
Diarrhea	3	3	5	4	4
General disorders and	administration	site conditions			
Fatigue	6	7	7	15	9
Gait disturbance	<1	<1	2	4	2
Asthenia	1	2	2	4	2
Injury, poisoning and p	rocedural com	plications			
Contusion	3	3	4	2	3
Skin laceration	2	2	3	3	3
Nervous system disord	ers	•			
Dizziness	8	16	30	53	31
Headache	9	11	14	12	13
Ataxia	2	4	7	15	8
Somnolence	5	5	8	8	7
Tremor	4	4	6	12	7
Nystagmus	4	2	5	10	5
Balance disorder	0	1	5	6	4
Memory impairment	2	1	2	6	2
Psychiatric disorders					
Depression	1	2	2	2	2

 $^{*}600\,mg$ dose is 1.5 times greater than the maximum recommended dose.

The overall adverse reaction rate was similar in male and female patients. Although there were few non-Caucasian patients, no differences in the incidences of adverse reactions compared to Caucasian patients were observed.

acosamide Tablet in Pediatric Patients

Safety of lacosamide was evaluated in clinical studies of pediatric patients 4 to less than 17 years of age for the treatment of partial-onset seizures. Across studies in pediatric patients with partial-onset seizures, 328 patients 4 to less than 17 years of age received lacosamide oral solution or tablet, of whom 148 received lacosamide for at least 1 year. Adverse reactions reported in clinical studies of pediatric patients 4 to less than 17 years of age were similar to those seen in adult patients.

Laboratory Abnormalities

Skin and subcutaneous disorder

Abnormalities in liver function tests have occurred in controlled trials with lacosamide in adult patients with partial-onset seizures who were taking 1 to 3 concomitant anti-epileptic drugs. Elevations of ALT to $\geq 3 \times$ ULN occurred in 0.7% (7/935) of lacosamide patients and 0% (0/356) of placebo patients. One case of hepatitis with transaminases >20x ULN occurred in one healthy subject 10 days after lacosamide treatment completion, along with nephritis (proteinuria and urine casts). Serologic studies were negative for viral hepatitis. Transaminase eturned to normal within one month without specific treatment. At the time of this event, bilirubin was normal The hepatitis/nephritis was interpreted as a delayed hypersensitivity reaction to lacosamide.

Other Adverse Reactions

The following is a list of adverse reactions reported by patients treated with lacosamide in all clinical trials in adult batients, including controlled trials and long-term open-label extension trials. Adverse reactions addressed in other tables or sections are not listed here. Blood and lymphatic system disorders: neutropenia, anemia Cardiac disorders: palpitations Ear and labyrinth disorders: tinnitus astrointestinal disorders: constipation, dyspepsia, dry mouth, oral hypoaesthesia General disorders and administration site conditions: irritability, pyrexia, feeling drunk Injury, poisoning, and procedural complications: fall Musculoskeletal and connective tissue disorders: muscle spasms Nervous system disorders: paresthesia, cognitive disorder, hypoaesthesia, dysarthria, disturbance in attention, Psychiatric disorders: confusional state, mood altered, depressed mood Additional pediatric use information is approved for UCB, Inc.'s VIMPAT® (lacosamide) tablets. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of lacosamide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: Agranulocytosis Bychiatric disorders: Aggression, agitation, hallucination, insomnia, psychotic disorder Skin and subcutaneous tissue disorders: Angioedema, rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis. ologic disorders: Dyskinesia, new or worsening seizures

DRUG INTERACTIONS

7.1 Strong CYP3A4 or CYP2C9 Inhibitors nts with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to lacosamide. Dose reduction may be necessary in these patients.

7.2 Concomitant Medications that Affect Cardiac Conduction

Lacosamide should be used with caution in patients on concomitant medications that affect cardiac conduction (sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers) including those that prolong PR interval (including sodium channel blocking AEDs), because of a risk of AV block, bradycardi, or ventricular tachyarrhythmia. In such patients, obtaining an EGG before beginning lacosamide, and after lacosamide is titrated to steady-state, is recommended. In addition, these patients should be closely monitored if they are administered lacosamide through the intravenous route (see Warnings and Precautions (5.3)

USE IN SPECIFIC POPULATIONS

Pregnancy 8.1 Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as lacosamide, during pregnancy. Encourage women who are taking lacosamide during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry by calling to 2004 previous the future of the second s 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/.

ere are no adequate data on the developmental risks associated with the use of lacosamide in pregnant women.

Lacosamide produced developmental toxicity (increased embryofetal and perinatal mortality, growth deficit) in rats following administration during pregnancy. Developmental neurotoxicity was observed in rats following administration during a period of postnatal development corresponding to the third trimester of human pregnancy

Lacosamide is effectively removed from plasma by hemodialysis. Dosage supplementation of up to 50% following hemodialysis should be considere

8.7 Hepatic Impairmen

ed on data in adults, for adult and pediatric patients with mild to moderate hepatic impairment, a reduction of 25% of the maximum dosage is recommended. Patients with mild to moderate hepatic impairment should be bserved closely during dose titration [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].

The pharmacokinetics of lacosamide has not been evaluated in severe hepatic impairment. Lacosamide use is not recommended in patients with severe hepatic impairment.

DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance Lacosamide is a Schedule V controlled substance

9.2 Abuse

In a human abuse potential study, single doses of 200 mg and 800 mg lacosamide produced euphoria-type subjective responses that differentiated statistically from placebo; at 800 mg, these euphoria-type responses were statistically indistinguishable from those produced by alprazolam, a Schedule IV drug. The duration of the euphoria-type responses following lacosamide was less than that following alprazolam. A high rate of euphoria was also reported as an adverse event in the human abuse potential study following single does of 800 mg lacosamide (15% [5/34]) compared to placebo (0%) and in two pharmacokinetic studies following single and multiple dose of 300 mg to 800 mg tacosamide (ranging from 6% [2/33] to 25% [3/12]) compared to placebo (0%). However, the rate of euphoria reported as an adverse event in the lacosamide development program at therapeutic doses was less than 1%.

9.3 Dependence Abrupt termination of lacosamide in clinical trials with diabetic neuropathic pain patients produced no signs or symptoms that are associated with a withdrawal syndrome indicative of physical dependence. However, psychological dependence cannot be excluded due to the ability of lacosamide to produce euphoria-type adverse events in humans.

Front

Side

570

mm

10 OVERDOSAGE Events reported after an intake of more than 800 mg (twice the maximum recommended daily dosage) of Lacosamide include dizziness, nausea, and seizures (generalized tonic-clonic seizures, status epilepticus). Cardiac conduction disorders, confusion, decreased level of consciousness, cardiogenic shock, cardiac arrest, and coma have also been observed. Fatalities have occurred following lacosamide overdoses of several grams.

There is no specific antidote for overdose with lacosamide. Standard decontamination procedures should be followed. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of patient. A Certified Poison Control Center should be contacted for up to date information on the management of overdose with lacosamide.

Standard hemodialysis procedures result in significant clearance of lacosamide (reduction of systemic exposure by 50% in 4 hours). Hemodialysis may be indicated based on the patient's clinical state or in patients with significant renal impairment.

Lacosamide is a white to light yellow powder. It is sparingly soluble in water and slightly soluble in acetonitrile and

Lacosamide tablets, USP contain the following inactive ingredients: microcrystalline cellulose, low substituted

hydroxypropyl cellulose, crospovidone, hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate,

12.1 Mechanism of Action The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully

elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes

A pharmacokinetic-pharmacodynamic (efficacy) analysis was performed based on the pooled data from the

a efficacy trials for partial-onset sezures. Lacosanide exposure is correlated with the reduction in sezure frequency. However, doses above 400 mg/day do not appear to confer additional benefit in group analyses.

Electrocardiographic effects of lacosamide were determined in a double-blind, randomized clinical

pharmacology trial of 247 healthy subjects. Chronic oral doses of 400 and 800 mg/day were compared with

placebo and a positive control (400 mg moxifloxacin). Lacosamide did not prolong QTc interval and did not have a dose-related or clinically important effect on QRS duration. Lacosamide produced a small, dose-related increase in mean PR interval. At steady-state, the time of the maximum observed mean PR interval corresponded with t_{max}

The placebo-subtracted maximum increase in PR interval (at t___) was 7.3 ms for the 400 mg/day group and 11.9 ms for the 800 mg/day group. For patients who participated in the controlled trials, the placebo-subtracted mean maximum increase in PR interval for a 400 mg/day lacosamide dose was 3.1 ms in patients with

The pharmacokinetics of lacosamide has been studied in healthy adult subjects (age range 18 to 87), adults with

Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%. The maximum lacosamide plasma concentrations occur approximately

1 to 4 hour post-dose after oral dosing, and elimination half-life is approximately 13 hours. Steady state plasma concentrations are achieved after 3 days of twice daily repeated administration. Pharmacokinetics of lacosamide

is dose proportional (100 mg to 800 mg) and time invariant, with low inter- and intra-subject variability. Compared

to lacosamide the major metabolite, 0-desmethyl metabolite, has a longer T_{max} (0.5 to 12 hours) and elimination

Lacosamide is completely absorbed after oral administration. The oral bioavailability of lacosamide tablets is

After intravenous administration, C., is reached at the end of infusion. The 30- and 60-minute intravenous

Inductions are bioequivalent to the oral tablet. For the 15-minute intravenous influsion, bioequivalence was met for AUC₆₋₂₁ but not for C_{max} . The point estimate of C_{max} was 20% higher than C_{max} for oral tablet and the 90% CI for C_{max} .

partial-onset seizures, adults with diabetic neuropathy, and subjects with renal and hepatic impairment. The pharmacokinetics of lacosamide is similar in healthy subjects, patients with partial-onset seizures, and patients

Lacosamide tablets, USP are supplied as debossed tablets and contain the following coloring agents:

DESCRIPTION The chemical name of lacosamide, USP, the single (R)-enantiomer, is (R)-2-acetamido-N-benzyl-3-methoxypropionamide (IUPAC). Lacosamide, USP is a functionalized amino acid. Its molecular formula is

11.1 Lacosamide Tablets. USP

100 mg tablets: yellow iron oxide

12 CLINICAL PHARMACOLOGY

and inhibition of repetitive neuronal firing.

12.2 Pharmacodynamics

Cardiac Electrophysiology

12.3 Pharmacokinetics

half-life (15 to 23 hours).

Absorption and Bioavailability

with primary generalized tonic-clonic seizures.

 $C_{13}H_{18}N_2O_3$ and its molecular weight is 250.29. The chemical structure is:

polyvinyl alcohol, talc, titanium dioxide, polyethylene glycol and soya lecithin

0 mg tablets: red iron oxide, FD&C Blue #2 and black iron oxide

150 mg tablets: yellow iron oxide, red iron oxide and black iron oxide 200 mg tablets: FD&C Blue #2

partial-onset seizures and 9.4 ms for patients with diabetic neuropathy.

oximately 100%. Food does not affect the rate and extent of abso

The dose titration should be performed with caution in patients with hepatic impairment Lacosamide use is not recommended in patients with severe hepatic impairment.

Concomitant Strong CYP3A4 and CYP2C9 Inhibitors Dose reduction may be necessary in patients with hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 [see Drug Interactions (7.1), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)].

2.5 Administration Instructions for Lacosamide Tablet Lacosamide tablets may be taken with or without food.

Lacosamide tablets Lacosamide tablets should be swallowed whole with liquid. Do not divide lacosamide tablets. Atrial Fibrillation and Atrial Flutter

5.4 Syncope

In the short-term investigational trials of lacosamide in adult patients with partial-onset seizures there were no cases of atrial fibrillation or flutter. Both atrial fibrillation and atrial flutter have been reported in open label partialonset seizure trials and in postmarketing experience. In adult patients with diabetic neuropathy, for which lacosamide is not indicated, 0.5% of patients treated with lacosamide experienced an adverse reaction of atrial fibrillation or atrial flutter, compared to 0% of placebo-treated patients. Lacosamide administration may predispose to atrial arrhythmias (atrial fibrillation or flutter), especially in patients with diabetic neuropathy and/or cardiovascular disease.

In the short-term controlled trials of lacosamide in adult patients with partial-onset seizures with no significant

system illnesses, there was no increase in syncope compared to placebo. In the short-term controlled trials in adult patients with diabetic neuropathy, for which lacosamide is not indicated, 1.2% of patients who were treated

se effects were observed at doses associated with clinically relevant plasma ex

In the U.S. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

Animal Data

Oral administration of lacosamide to pregnant rats (20, 75, or 200 mg/kg/day) and rabbits (6.25, 12.5, or 25 mg/kg/day) during the period of organogenesis did not produce any effects on the incidences of fetal structural abnormalities. However, the maximum doses evaluated were limited by maternal toxicity in both species and embryofetal death in rats. These doses were associated with maternal plasma lacosamide exposures (AU approximately 2 and 1 times (rat and rabbit, respectively) that in humans at the maximum recommended human dose (MRHD) of 400 mg/day.

In a trial comparing the oral tablet with an oral solution containing 10 mg/mL lacosamide, bioequivalence betwee both formulations was shown.

A single loading dose of 200 mg approximates steady-state concentrations comparable to the 100 mg twice dail oral administration

The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water. Lacosamide s less than 15% bound to plasma proteins

Aetabolism and Elimination ed from the systemic circulation by renal excretion and biotrans mide is primarily elir

KLD_OPEN SIZE : 570mm X 380 mm / CLOSE SIZE : 34 X 35 MM 17/5/2018



	380 r	nm	
	<u>35 mm</u>	10	7.5
157.5 mm		18/	7.5 mm
r oral administration of 100 mg [14C]-lacosamide approximately 95% of radioactivity administered was vered in the urine and less than 0.5% in the feces. The major compounds excreted were unchanged samide (approximately 40% of the dose), its O-desmethyl metabolite (approximately 30%), and a structurally own polar fraction (~20%). The plasma exposure of the major human metabolite, O-desmethyl-samide, is approximately 10% of that of lacosamide. This metabolite has no known pharmacological activity. CYP isoforms mainly responsible for the formation of the unchanged drug is approximately 13 hours and is not ed by different doses, multiple dosing or intravenous administration.	phase). During the titration phase, in all 3 adjunctive therapy trials, treatment was initiated at 100 mg/day (50 mg twice daily), and increased in weekly increments of 100 mg/day to the target dose. The titration phase lasted 6 weeks in Study 2 and Study 3, and 4 weeks in Study 4. In all three trials, the titration phase was followed by a maintenance phase that lasted 12 weeks, during which patients were to remain on a stable dose of lacosamide. A reduction in 28 day seizure frequency (baseline to maintenance phase), as compared to the placebo group, was the primary variable in all three adjunctive therapy trials. A statistically significant effect was observed with lacosamide treatment (Figure 1) at doses of 200 mg/day (Study 4), 400 mg/day (Studies 2, 3, and 4), and	2. Lacosamide tablets may cause you to feel dizzy, have double vision, feel sleepy, or have problems with coordination and walking. Do not drive, operate heavy machinery, or do other dangerous activities until you know how lacosamide tablets affects you. 3. Lacosamide tablets may cause you to have an irregular heartbeat or may cause you to faint. In rare cases, cardiac arrest has been reported. Call your healthcare provider right away if you: have a fast, slow, or pounding heartbeat or feel your heart skip a beat have chest pain have chest pain 	
e is no enantiomeric interconversion of lacosamide. <u>ific Populations</u> <i>I Impairment</i> samide and its major metabolite are eliminated from the systemic circulation primarily by renal excretion.	600 mg/day (Studies 2 and 3). Subset evaluations of lacosamide demonstrate no important differences in seizure control as a function of gender or race, although data on race was limited (about 10% of patients were non-Caucasian). Figure 1- Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose	 fainted or if you feel like you are going to faint If you have fainted or feel like you are going to faint you should lay down with your legs raised. Lacosamide is a federally controlled substance (CV) because it can be abused or lead to drug dependence. Keep your lacosamide tablets in a safe place, to protect it from theft. Never give your lacosamide tablets to anyone else, because it may harm them. Selling or giving away this medicine is against the law. 	
AUC of lacosamide was increased approximately 25% in mildly (CL_{cn} 50 to 80 mL/min) and moderately 30 to 50 mL/min) and 60% in severely ($CL_{cn} \leq 30$ mL/min) renally impaired patients compared to subjects normal renal function ($CL_{cn} \geq 80$ mL/min), whereas C_{max} was unaffected. Lacosamide is effectively removed plasma by hemodialysis. Following a 4-hour hemodialysis treatment, AUC of lacosamide is reduced by wimately 50% [see Dosage and Administration (2.3)].	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	What are lacosamide tablets? Lacosamide tablets are a prescription medicine used: • to treat partial-onset seizures in people 4 years of age and older. It is not known if lacosamide tablets are safe and effective for partial-onset seizures in children under 1 month of age.	
samide undergoes metabolism. Subjects with moderate hepatic impairment (Child-Pugh B) showed higher na concentrations of lacosamide (approximately 50 to 60% higher AUC compared to healthy subjects). The nacokinetics of lacosamide have not been evaluated in severe hepatic impairment [see Dosage and nistration (2.4)]. tric Patients (4 to less than 17 Years of Age) editatric pharmacokinetic profile of lacosamide was determined in a population pharmacokinetic analysis sparse plasma concentration data obtained in two open-label studies in 79 pediatric patients with epilepsy	40% 40% 37% 38% 38% 30% 25% 21% 21% 21% 21% 21% 21% 21% 21	What should I tell my healthcare provider before taking lacosamide tablets? Before you take lacosamide tablets, tell your healthcare provider about all of your medical conditions, including if you: have or have had depression, mood problems or suicidal thoughts or behavior. have heart problems. have kidney problems. have liver problems. have biver problems. have biver problems. have biver problems.	
4 years to less than 17 years who received oral solution or oral tablet formulations. In the based dosing regimen is necessary to achieve lacosamide exposures in pediatric patients 4 years to less 7 years of age similar to those observed in adults treated at effective doses of lacosamide [see Dosage and <i>istration</i> (2.1)]. For patients weighing 11 kg, 28.9 kg (the mean population body weight), and 70 kg, the I plasma half-life (t1/2) is 7.4 hours, 10.6 hours, and 14.8 hours, respectively. Steady state plasma ntrations are achieved after 3 days of twice daily repeated administration.	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	 are pregnant or plan to become pregnant. It is not known if lacosamide tablets can harm your unborn baby. Tell your healthcare provider right away if you become pregnant while tablets can harm your unborn baby. Tell your healthcare provider will decide if you should take lacosamide tablets while you are pregnant. If you become pregnant while taking lacosamide tablets, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about 	
pharmacokinetics of lacosamide in pediatric patients are similar when used as monotherapy or as adjunctive py for the treatment of partial-onset seizures. tional pediatric use information is approved for UCB, Inc.'s VIMPAT® (lacosamide) tablets. However, due to	* Statistically significant difference as compared to placebo. Figure 2 presents the percentage of patients (X-axis) with a percent reduction in partial seizure frequency	 the safety of antiepileptic medicine during pregnancy. are breastfeeding or plan to breastfeed. It is not known if lacosamide passes into your breast milk or if it can harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take lacosamide tablets. 	
Incluse periodic use information is approved for OCB, incluse view of labeled with that pediatric information. Incluse marketing exclusivity rights, this drug product is not labeled with that pediatric information. tric Patients e elderly (>65 years), dose and body-weight normalized AUC and C _{mm} is about 20% increased compared to g subjects (18 to 64 years). This may be related to body weight and decreased renal function in elderly sets.	(responder rate) from baseline to the maintenance phase at least as great as that represented on the Y-axis. A positive value on the Y-axis indicates an improvement from baseline (i.e., a decrease in seizure frequency), while a negative value indicates a worsening from baseline (i.e., an increase in seizure frequency). Thus, in a display of this type, a curve for an effective treatment is shifted to the left of the curve for placebo. The proportion of patients achieving any particular level of reduction in seizure frequency was consistently higher for the lacosamide groups, compared to the placebo group. For example, 40% of patients randomized to lacosamide (400 mg/day)	Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. Taking lacosamide tablets with certain other medicines may cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist each time you get a new medicine.	
er samide clinical trials indicate that gender does not have a clinically relevant influence on the nacokinetics of lacosamide. are no clinically relevant differences in the pharmacokinetics of lacosamide between Asian, Black, and	experienced a 50% or greater reduction in seizure frequency, compared to 23% of patients randomized to placebo. Patients with an increase in seizure frequency >100% are represented on the Y-axis as equal to or greater than -100%. Figure 2 - Proportion of Patients by Responder Rate for Lacosamide and Placebo, Groups in Studies 2, 3, and 4	 How should I take lacosamide tablets? Take lacosamide tablets exactly as your healthcare provider tells you. Your healthcare provider will tell you how many lacosamide tablets to take and when to take it. Your healthcare provider may change your dose if needed. Do not stop lacosamide tablets without first talking to a healthcare provider. Stopping lacosamide tablets suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). 	
ucasian subjects. <i>P2C19Polymorphism</i> ere are no clinically relevant differences in the pharmacokinetics of lacosamide between CYP2C19 poor tabolizers and extensive metabolizers. Results from a trial in poor metabolizers (PM) (N=4) and extensive	100%- E 75%-	 Eacosamide tablets may be taken with or without food. Swallow lacosamide tablets whole with liquid. Do not cut lacosamide tablets. If you take too many lacosamide tablets, call your healthcare provider or local Poison Control Center right away. 	


metabolizers and extensive metabolizers. Results from a trial in poor metabolizers (PM) (N=4) and extensive metabolizers (EM) (N=8) of cvtochrome P450 (CYP) 2C19 showed that lacosamide plasma concentrations

50% -Ы 25%-

tablets affects you. Lacosamide tablets may cause you to feel dizzy, have double vision, feel sleepy, or have problems with coordination and walking.

03/2022

ISS. 5 2 3



Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during lacosamide tablets therapy. Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry if they become pregnant. This registry is collecting information about the safety of AEDs ing pregnancy [see Use in Specific Populations (8.1)]

The efficacy of lacosamide in monotherapy was established in a historical-control, multicenter, randomized trial that included 425 patients, age 16 to 70 years, with partial-onset seizures (Study 1). To be included in Study 1, Dispense with Medication Guide available at: https://www.sunpharma.com/usa/products

MEDICATION GUIDE Lacosamide (la KOE sa mide) Tablets, USP, for oral use 🕑

Read this Medication Guide before you start taking lacosamide tablets and each time you get a refill. There may be new information. This Medication Guide describes important safety information about lacosamide tablets. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is the most important information I should know about lacosamide tablets? Do not stop taking lacosamide tablets without first talking to your healthcare provider. Stopping lacosamide tablets suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

mide tablets can cause serious side effects, including:

Like other antiepileptic drugs, lacosamide tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

Call a healthcare provider right away if you have any of these symptoms, especially if they are

- new, worse, or worry you:
 thoughts about suicide or dying
- attempt to commit suicide new or worse depression

For the lacosamide 400 mg/day group, the estimate of the percentage of patients meeting at least 1 exit criterion was 30% (95% CI: 25%, 36%). The upper limit of the 2-sided 95% CI (36%) was below the threshold of new or worse anxiety

 feeling agitated or restless 65% derived from the historical control data, meeting the pre-specified criteria for efficacy. Lacosamide panic attacks

trouble sleeping (insomnia)
new or worse irritability acting aggressive, being

Back 570 mm Side

14.2 Adjunctive Therapy in Patients with Partial-Onset Seizures The efficacy of lacosamide as adjunctive therapy in partial-onset seizures was established in three 12-week randomized, double-blind, placebo-controlled, multicenter trials in adult patients (Study 2, Study 3, and Study 4) Enrolled patients had partial-onset seizures with or without secondary generalization, and were not adequately controlled with 1 to 3 concomitant AEDs. During an 8-week baseline period, patients were required to have an average of ≥ 4 partial-onset seizures per 28 days with no seizure-free period exceeding 21 days. In these 3 trials, patients had a mean duration of epilepsy of 24 years and a median baseline seizure frequency ranging from 10 to 17 per 28 days. 84% of patients were taking 2 to 3 concomitant AEDs with or without concurrent vagal nerve

exposures (AUC) up to approximately 2 times the plasma AUC in humans at the MRHD.

patients were required to be taking stable doses of 1 or 2 marketed antiepileptic drugs. This treatment continued

into the 8 week baseline period. To remain in the study, patients were required to have at least 2 partial-onset seizures per 28 days during the 8 week baseline period. The baseline period was followed by a 3 week titration

period, during which lacosamide was added to the ongoing antiepileptic regimen. This was followed by a

16-week maintenance period (i.e., a 6-week withdrawal period for background antiepileptic drugs, followed by a 10-week monotherapy period). Patients were randomized 3 to 1 to receive lacosamide 400 mg/day or lacosamide 300 mg/day. Treatment assignments were blinded. Response to treatment was based upon a comparison of the number of patients who met exit criteria during the maintenance phase, compared to historical

controls. The historical control consisted of a pooled analysis of the control pruos from 8 studies of similar design, which utilized a sub-therapeutic dose of an antiepileptic drug. Statistical superiority to the historical control was considered to be demonstrated if the upper limit from a 2-sided 95% confidence interval for the

percentage of patients meeting exit criteria in patients receiving lacosamide remained below the lower 95% prediction limit of 65% derived from the historical control data.

The exit criteria were one or more of the following: (1) doubling of average monthly seizure frequency during any

28 consecutive days, (2) doubling of highest consecutive 2-day seizure frequency, (3) occurrence of a single generalized tonic-clonic seizure, (4) clinically significant prolongation or worsening of overall seizure duration, frequency, type or pattern considered by the investigator to require trial discontinuation, (5) status epilepticus or new onset of serial/cluster seizures. The study population profile appeared comparable to that of the historical executive activities.

CLINICAL STUDIES
 Monotherapy in Patients with Partial-Onset Seizures

300 mg/day also met the pre-specified criteria for efficacy

control population

Study 2 compared doses of lacosamide 200, 400, and 600 mg/day with placebo. Study 3 compared doses of lacosamide 400 and 600 mg/day with placebo. Study 4 compared doses of lacosamide 200 and 400 mg/day with placebo. In all three trials, following an 8-week baseline phase to establish baseline seizure frequency prior to randomization, patients were randomized and titrated to the randomized dose (a 1-step back-titration o lacosamide 100 mg/day or placebo was allowed in the case of intolerable adverse events at the end of the titration

- acting on dangerous impulses
 an extreme increase in activity and talking (mania) other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions?
- · Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or
- Keep all follow-up visits with your healthcare provider as scheduled. · Call your healthcare provider between visits as needed, especially if you are worried about
- symptoms. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicida thoughts or actions, your healthcare provider may check for other causes.

KLD_OPEN SIZE : 570mm X 380 mm / CLOSE SIZE : 34 X 35 MM 17/5/2018 Size: 380x570 mm